Bodelwyddan

Researchers are evaluating the cannabinoid Nabiximols Sativex added to the standard chemotherapy temozolomide TMZ in patients with recurrent MGMT methylated glioblastoma GBM. This phase II, multi-center, double-blind, placebo-controlled, randomized trial aims to compare Nabiximols with a matched placebo alongside TMZ treatment. The study is linked with the Tessa Jowell BRAIN MATRIX program to streamline patient entry and data sharing while providing additional oversight. Participants will be randomly assigned in a 21 ratio to receive either Nabiximols or placebo, both combined with temozolomide. Temozolomide is given orally once daily on days 1-5 of each 28-day cycle, starting at 150mgm2 in cycle 1 and increasing to 200mgm2 in subsequent cycles, for up to six cycles. Nabiximols or placebo sprays are self-titrated up to 12 sprays per day over the first 14 days of cycle 1, continuing for up to six cycles. Patients will attend 4-weekly follow-up visits for at least 52 weeks or until death. MRI scans are scheduled at screening, weeks 10, 22, 30, and then every three months after starting treatment. Researchers will monitor overall survival, progression-free survival, health-related quality of life, and adverse events. The initial 40 patients will be evaluated for safety, compliance, and recruitment feasibility before continuing the trial. Total participation may last up to a year or more depending on individual outcomes.

Researchers are studying muvalaplin to see if it can reduce the risk of major heart problems in adults with high levels of lipoproteina who have cardiovascular disease or are at risk of a heart attack or stroke. This Phase 3 trial is designed to provide strong evidence by comparing muvalaplin to a placebo in a large group of participants over several years. The study is sponsored by Eli Lilly and Company and focuses on adults with atherosclerotic cardiovascular disease or those at risk for it. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken by mouth. The trial is double-blind, meaning neither the participants nor the researchers know who receives the active drug or placebo. The study will last about 5.25 years, during which participants will be monitored closely. The primary goal is to measure the time until the first major adverse cardiac event occurs, including heart attacks and strokes. During the study, participants will have regular visits for assessments, including blood tests to measure lipoproteina levels and pharmacokinetics of muvalaplin over the first 96 weeks. Researchers will track the occurrence of cardiovascular events, deaths, and healthcare resource use annually. Safety and adherence will be monitored throughout the study to ensure participant well-being and accurate data collection.

Researchers are evaluating the efficacy and safety of bomedemstat compared with hydroxyurea in adults diagnosed with essential thrombocythemia ET who have not previously received cytoreductive therapy but require it. The main goal is to see if bomedemstat can provide a better durable clinicohematologic response DCHR than hydroxyurea. This Phase 3, randomized, double-blind trial aims to improve treatment options for people with ET by comparing these two therapies. Participants will be randomly assigned to receive either active bomedemstat with a placebo for hydroxyurea or active hydroxyurea with a placebo for bomedemstat. Both treatments are given as oral capsules daily for up to 52 weeks, with doses adjusted to safely reduce platelet counts within a target range. After completing the initial treatment period, eligible participants may continue treatment in an extended phase. Placebos will be stopped and unblinding will occur once all participants finish or discontinue the 52-week therapy. During the study, participants will have regular assessments to monitor blood counts, symptom changes using specific fatigue and symptom questionnaires, and the occurrence of thrombotic or hemorrhagic events. Researchers will evaluate durable hematologic remission and disease progression up to Week 52. Safety will be closely followed through adverse event tracking. The total study participation includes the initial 52-week treatment and possible extension, with detailed monitoring throughout to assess treatment effects and safety.

Researchers are conducting an international, randomized phase III trial called RADAR to compare two chemotherapy regimens, ABVD and A2VD, in patients with early-stage Hodgkin lymphoma. This study aims to evaluate how well these treatments work and adapt therapy based on PET-CT scan results after two cycles. The trial is led by University College London and the Canadian Cancer Trials Group, combining data from Europe, AustraliaNew Zealand, and North America to achieve the total sample size. Participants will be randomly assigned to receive either ABVD chemotherapy doxorubicin, bleomycin, vinblastine, and dacarbazine or A2VD chemotherapy doxorubicin, brentuximab vedotin, vinblastine, and dacarbazine with growth factor support. After two cycles, a PET-CT scan will guide further treatment patients with favorable scan results will receive one more chemotherapy cycle those with less favorable results will receive two more cycles plus involved site radiotherapy and those with the least favorable results will stop trial treatment and receive other care as decided by their doctor. Some patients may also have an additional PET-CT scan to confirm treatment response. During the study, participants will have PET-CT scans to monitor disease response, and researchers will follow them for at least five years after treatment ends. The main outcome measured is progression-free survival at three years, with additional assessments including event-free survival, overall survival, safety, toxicity, and incidence of second cancers or cardiovascular disease. Patients will be closely monitored for side effects and treatment response throughout the trial.

Researchers are conducting a randomized phase III clinical trial to evaluate treatments for patients with unilateral malignant pleural mesothelioma MPM. The study aims to compare progression-free survival and overall survival between two groups. It also assesses safety, tolerability, quality of life, and local disease control. Patients are grouped based on tumor histology, treatment center, tumor location, and time since diagnosis. Participants are randomly assigned to one of two groups. The experimental group receives proton beam therapy PBT to the hemithorax 50 Gy in 25 daily fractions over five weeks, with a boost to 60 Gy for visible tumors. The control group follows standard care with active surveillance and no immediate treatment. Both groups are monitored for two years after randomization, with clinic visits every three months in the first year and every four months in the second year. If disease progresses in the control group, patients may receive immunotherapy or chemotherapy based on doctor recommendation. During the study, patients undergo evaluations including scans, pulmonary function tests, and quality of life questionnaires. Researchers track adverse events related to proton therapy and collect data on healthcare resource use and informal care. Follow-up occurs at local centers for two years after treatment start. The main outcomes measured are time to disease progression and overall survival, assessing the potential benefits and risks of proton beam therapy for MPM.

This research investigates whether personalized medical treatment guided by a special diagnostic procedure during invasive coronary angiography can improve symptoms, wellbeing, cardiovascular risk, and clinical outcomes in patients with angina but no significant blockage in their coronary arteries. It focuses on patients with ischaemic heart disease, particularly those with angina without obstructive coronary artery disease INOCA, a condition affecting the small vessels of the heart. The trial builds on earlier pilot studies that suggested this approach could improve quality of life and symptom control by tailoring diagnosis and treatment more precisely. Participants undergo functional coronary angiography with a guidewire-based interventional diagnostic procedure IDP that measures coronary vascular function to classify patients into specific diagnosis groups, such as microvascular or vasospastic angina. Eligible patients are randomized into two groups one where IDP results are disclosed to clinicians to guide treatment, and another where IDP is performed but results are hidden, with care based on standard angiography and clinical information. Both groups receive medical therapy and lifestyle advice based on their diagnosis. The study also includes a registry for patients with obstructive disease who are not randomized. During the study, participants complete symptom questionnaires like the Seattle Angina Questionnaire to assess their angina symptoms and quality of life over at least 12 months. Researchers monitor health status, clinical outcomes, safety, and health economics, with ongoing follow-up planned for up to 10 years. Both patients and their usual care clinicians are blinded to the group allocation, but informed about the diagnosis to guide treatment. The trial aims to enroll 1500 participants across multiple centers in Europe, assessing the feasibility and impact of this stratified medicine approach.

Researchers are evaluating the study medicine called elranatamab in people with multiple myeloma MM that has returned or not responded to previous treatments, including prior anti-CD38 antibody and lenalidomide therapies. This Phase 3 trial aims to compare elranatamab with other commonly used combination therapies to understand its safety and how well it works for people with relapsed or refractory MM. Participants will be randomly assigned to receive either elranatamab alone or an investigators choice of combination therapies. Elranatamab is given as a weekly shot under the skin at the study clinic, which may become less frequent later. The combination therapies include various medicines taken by mouth and given as shots or intravenous infusions at the clinic. Treatment continues until the MM no longer responds. During the study, participants will visit the clinic regularly for monitoring and assessments, including evaluations of disease progression and response to treatment. Follow-up contacts by telephone or visits will continue after treatment ends. The main measure is progression-free survival, and other outcomes include overall survival, response rates, quality of life, and safety. The study may last up to about five years for some measures.

Researchers are evaluating palazestrant OP-1250 compared to standard endocrine therapies for adults with ER-positive, HER2-negative advanced or metastatic breast cancer that has progressed after endocrine therapy combined with a CDK46 inhibitor. This international phase 3 trial aims to assess the safety and effectiveness of palazestrant versus fulvestrant or aromatase inhibitors such as anastrozole, letrozole, or exemestane. Participants are randomly assigned to receive either palazestrant daily on a 28-day cycle at doses of 90 mg or 120 mg during the dose-selection phase, or the standard-of-care endocrine therapy including fulvestrant administered on specific days or one of the aromatase inhibitors given daily on similar cycles. The trial includes an initial dose-selection period with about 120 participants, followed by a larger randomized phase with approximately 390 participants receiving the selected dose of palazestrant or standard treatment. Throughout the study, participants will be monitored for adverse events, dose adjustments, and drug discontinuations up to 16 weeks. Researchers will measure progression-free survival for up to two years and overall survival for up to four years after randomization. Regular assessments will include clinical evaluations and safety monitoring to observe the effects and tolerability of the treatments during the trial.

Researchers are evaluating treatments for community-acquired pneumonia CAP, especially in patients admitted to intensive care units ICUs. This trial also adapts to study treatments for respiratory pandemics like COVID-19. The goal is to determine which treatment strategies improve outcomes for patients with severe pneumonia, using a flexible, ongoing approach that can test multiple therapies simultaneously and update as new information becomes available. Participants receive different treatment strategies based on random assignment to study groups. Treatments include various antibiotics, steroids, antivirals, immune modulators, anticoagulation methods, and ventilation strategies. Some treatment options have been closed to recruitment, reflecting the trials adaptive nature. The trial includes several domains targeting specific infections such as influenza and COVID-19, with dosing and duration guided by clinical practice and local guidelines. During the study, participants are monitored closely with assessments including survival up to 90 days, days alive without organ support in ICU, ICU and hospital length of stay, ventilator-free days, organ failure-free days, and quality of life up to 6 months. Researchers collect detailed data on patient outcomes, organ support needs, and hospital discharge status. The study runs until February 2028, with ongoing evaluation to improve pneumonia treatment strategies in ICU settings and during respiratory pandemics.

Rapid Diagnostic Centres RDCs are designed to quickly diagnose patients who show common symptoms that might be related to cancer, such as weight loss, fatigue, cough, or a general practitioners suspicion. This observational study aims to develop new blood or non-blood tests that help doctors identify which patients have cancer and which are at higher risk, so they can be monitored or directed to appropriate screening programs. The study focuses on improving diagnosis and risk assessment in patients referred to RDCs, many of whom may not have cancer but could be at risk due to inherited or environmental factors. The study collects breath, blood, and saliva samples from up to 1000 patients attending RDCs to develop tests that can detect cancer or assess cancer risk through polygenic risk scores. Samples are taken at the first appointment and follow-up visits if necessary. Patients provide consent and are assigned a unique Study ID to keep their information confidential. Clinical data, patient health questionnaires, and, for some, anonymized scans from medical records are also collected to support the development of diagnostic tools. Participants will provide samples and complete health surveys at their visits, with samples shipped to labs for analysis. The study will follow patients for 12 months after joining to confirm diagnoses and observe outcomes. Researchers will analyze clinical, genetic, imaging, and symptom data to develop models that distinguish between cancer and non-cancer cases. Patient data and samples will be stored for ten years to support future research and improved diagnostic methods.